Fresh approaches to early testing for dementia are increasingly common, but the resulting technology has tended to fall short in terms of results. London-based Cognetivity Neurosciences Ltd. has been developing a compelling solution, the ICA (Integrated Cognitive Assessment) test using natural images that are presented quickly to participants who are asked to accurately indicate whether they have seen a pre-specified image category. The test can be performed on an iPAD, potentially in any setting. The viewed images are processed in the visual cortex, a brain region associated with the earliest signs of neurodegeneration in conditions such as Alzheimer's disease (AD), and are translated to movement in the motor cortex, allowing evaluations to be made based on comparisons with an accurate dataset of clinically-diagnosed subjects. It is a technology that the company believes has applications in and beyond the clinical setting.
A ‘Blood Pressure Test’ For Dementia
Neuroscience Innovator Looks At Early Diagnosis From New Angle
The attention accorded to dementia, MCI and degenerative brain conditions has been slow to reach the levels given to the more visibly-quantifiable conditions, such as cardiovascular disease and oncology. But earlier detection of cognitive impairment is a priority, despite therapies not yet being available to halt or reverse the conditions. Playing its part to push back the boundaries is Cognetivity Neurosciences, a London-based company with an innovative tool that uses AI to test subjects for the early signs of dementia.
More from Innovation
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.
Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.
The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.
More from In Vivo
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.